GeYuan Group
GeYuan Group
GeYuan Investment Consulting, Inc. is a U.S.-based investment group focused on equity investments and investment consulting services.
GeYuan Group’s major investment portfolio in the U.S. includes:
- ETP Capital (Emerging Technology Partners, LLC)
- Vesta Corporation
- Amend Surgical, Inc.
- OriGene Technologies, Inc.
- CASI Pharmaceuticals, Inc.
- Sirnaomics Biotech Inc.
- RNA Immune Inc.
- Ark Pacific Special Opportunities Fund, and others.
GeYuan Group
GeYuan Group
Beijing GeYuan is primarily engaged in equity investment, investment consulting, investment management, corporate management consulting, and project investment advisory services. As an institutional investor, it has participated in equity investments in multiple listed and Pre-IPO companies.
GeYuan Group’s major investments in China include:
- Sinoway Investment Corporation
- KunMing Sinobright Department Store Co., Ltd.
- KunMing Sinoway Natural Pharmaceuticals Co., Ltd.
- Yunnan Lvdadi Biotechnology Co., Ltd.
- Shanghai Fanghe Investment Center（Limited Partnership）
- Shanghai Purun Phase IV Equity Investment Partnership Enterprise（Limited Partnership）
- Shanghai Fengrui Venture Investment Center (Limited Partnership)
- Tianjin Shangshi Venture Investment Fund, and others.
Our Team
Dao Feng He
FOUNDER & CEO
Angela He
CO-FOUNDER & CFO
Bin Yang
VP-INVESTMENT
Yingying Liu
VP-ADMINISTRATION
Ling Qin
VP-LEGAL AFFAIRS
Jade Lin
FINANCE MANAGER
GeYuan Group
